

Agenda: Chronic Illness Measures Workgroup 8-22-2014

9:00	Welcome and Introductions
9:05	Quick Review: <ul style="list-style-type: none">• Measure selection criteria• Decisions from August 7 meeting• New measures worksheet
9:15	Decision on Follow-up Items from August 7 meeting <ul style="list-style-type: none">• Depression Measure• COPD/Spirometry Testing• Drug and Alcohol – additional measures?• Feasibility of NQF #0004
9:45	Continue Measures Review <ul style="list-style-type: none">• Hypertension and Cardiovascular Disease• Medications – Adherence and Generic Use• Other• Revisit MAYBEs if any left
Time Permitting	Discussion of Units of Analysis for each Recommended Measure
10:50	Next Steps
10:55	Open Line for Comment

YES Measures To Date

Identifier (#)	Name of Measure	NQF #	Steward	Category	Data Source	Measure Description
116	Use of Appropriate Medications for Asthma (ASM)	0036	NCQA	Asthma	Claims	Percentage of patients 5-64 years of age who were identified as having persistent asthma and were appropriately prescribed medication during the measurement period.
119	Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	0577	NCQA	COPD	Claims	The percentage of patients 40 years of age and older with a new diagnosis of COPD or newly active COPD, who received appropriate spirometry testing to confirm the diagnosis.
13	Anti-depressant Medication Management (AMM)	0105	NCQA	Depression	Claims	Percentage of patients 18 years of age and older who were diagnosed with major depression and treated with antidepressant medication, and who remained on antidepressant medication treatment. Two rates are reported.
31	Comprehensive Diabetes Care: Eye Exam	0055	NCQA	Diabetes	Claims	Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period
37	Comprehensive Diabetes Care: Medical Attention for Nephropathy	0062	NCQA	Diabetes	Claims	The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period.
34	Comprehensive Diabetes Care: Hemoglobin A1c testing	0057	NCQA	Diabetes	Claims	The percentage of members 18-75 years of age with diabetes (type 1 and type 2) who received an HbA1c test during the measurement year.

YES Measures To Date

Identifier (#)	Name of Measure	NQF #	Steward	Category	Data Source	Measure Description
92	Pharmacy: Percent Generic (one rate for each: Antacid, Antidepressants, Statins, ACE and ARBS, ADHD)	NA	Washington Health Alliance	Medication Management and Generic Use	Claims	<ul style="list-style-type: none"> • Percentage of Generic Prescriptions for ACE inhibitors or angiotensin II receptor blockers (ARBs). • Percentage of Generic Prescriptions for attention deficit hyperactivity disorder (ADHD) Medications • Percentage of Generic Prescriptions for PPIs (proton pump inhibitors) • Percentage of Generic Prescriptions for SSRIs, SNRIs, and other Second Generation Antidepressants • Percentage of Generic Prescriptions for Statins

MAYBE MEASURES TO DATE

Identifier (#)	Name of Measure	NQF #	Steward	Category	Data Source	Measure Description
65	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET)	0004	NCQA	Drug and Alcohol Use	Claims	<p>The percentage of adolescent and adult patients with a new episode of alcohol or other drug (AOD) dependence who received the following.</p> <ul style="list-style-type: none"> - Initiation of AOD Treatment: Percentage of patients who initiate treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or partial hospitalization within 14 days of the diagnosis - Engagement of AOD Treatment: Percentage of patients who initiated treatment and who had two or more additional services with a diagnosis of AOD within 30 days of the initiation visit
18	ASCVD: Use of Statins	NA	American College of Cardiology & American Heart Association	Hypertension and Cardiovascular Disease	Claims	Cholesterol-Lowering Medication for Patients with Coronary Artery Disease
27	Cholesterol Management for Patients with Cardiovascular Conditions (LDL-C Screening)) (CMC)	NA	NCQA	Hypertension and Cardiovascular Disease	Claims and Clinical Data	<p>The percentage of members 18–75 years of age who were discharged alive for AMI, coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during the measurement year and the year prior to the measurement year, who had each of the following during the measurement year:</p> <ul style="list-style-type: none"> • LDL-C screening.

PARKING LOT TOPICS/MEASURES

Topic	Comments	Potential Measures for Future Consideration
Diabetes: Blood Pressure and HbA1c Control	There is strong interest in measures that ascertain intermediate outcomes, however, there is recognition that we are currently unable to reliably measure outcomes utilizing clinical data from the electronic or paper medical record for a broad segment of provider organizations.	<ul style="list-style-type: none"> Measure #30 (NQF #0061): The percentage of members 18-75 years of age with diabetes (type 1 and type 2) whose most recent blood pressure (BP) reading is <140/90 mm Hg during the measurement year. Measure #33 (NQF #0059): Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period.
Diabetes composite measure: Optimal Care	The work group would like to see the inclusion of a nationally-vetted composite measure that includes outcomes at the point which the Alliance is able to measure all of the components of the measure.	
Diabetes: ACE/ARB, Statins	The work group would like to see the inclusion of nationally-vetted measures to assess use of ACE inhibitor, angiotensin receptor blocker (ARB) and Statins in the diabetic population when they are developed.	
Cardiovascular Disease: Blood Pressure Control	Same as above under #1	<ul style="list-style-type: none"> Measure #38 (NQF #0018): The percentage of patients 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90) during the measurement year.

PARKING LOT TOPICS/MEASURES

Topic	Comments	Potential Measures for Future Consideration
Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder Medication (ADD)	This is a claims-based measure. Considered very important but not as a priority for the starter set. Consider for future measure sets.	<ul style="list-style-type: none"> Measure #50 (NQF #0108): Percentage of children newly prescribed ADHD medication that had at least three follow-up care visits within a 10-month period, one of which was within 30 days from the time the first ADHD medication was dispensed, including two rates: one for the initiation phase and one for the continuation and maintenance phase
Functional Status	The work group would like to consider adding a functional status measure at a future date. Currently, there are no functional status measures in wide use with readily available data for measurement and reporting.	
Additional asthma measures	The work group indicated interest in asthma measures related to adherence and outcomes going forward. With respect to outcomes, group expressed interest in utilization measures such as asthma hospital admission rates and ER utilization for asthma-related complications. Other outcome measures will require clinical data that we can't access at present. The work group would also like future consideration of a patient-experience asthma measure.	<ul style="list-style-type: none"> Asthma Medication Ratio (AMR) (NQF #1800) (Measure #171) Asthma: Pharmacologic Therapy (NQF #0047) (Measure #172) Medication Management for People with Asthma (MMA) (NQF #1799) (Measure #71) Suboptimal Asthma Control (SAC) and Absence of Controller Therapy (ACT) (NQF #0548) (Measure #173) Relative Resource Use for People with Asthma (NQF #1560) (Measure #174)- for use at the medical group level and not the health plan level Asthma: Assessment of Asthma Control (NQF#0001) (Measure #187)
Additional COPD measures	The work group would like consideration of a measure of medication compliance and therapy in the future.	
Screening and Control of depression	The work group would like future measure sets to include: Depression screening among patients with one or more chronic disease diagnoses Depression management through PHQ-9 results monitored over time	